Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Iveric Bio Inc (NQ: ISEE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iveric Bio Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study
Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA). 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
IVERIC bio Stock Soars After Encouraging Geographic Atrophy Trial Data
IVERIC bio Inc (NASDAQ: ISEE) announced positive data from the second Phase 3 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA).  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
What 5 Analyst Ratings Have To Say About IVERIC bio
Within the last quarter, IVERIC bio (NASDAQ:ISEE) has observed the following analyst ratings: 
Via Benzinga
IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch
Via Benzinga
Recap: IVERIC bio Q2 Earnings
  IVERIC bio (NASDAQ:ISEE) reported its Q2 earnings results on Tuesday, July 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
Earnings Scheduled For July 26, 2022
Companies Reporting Before The Bell • General Motors (NYSE:GM) is likely to report quarterly earnings at $1.30 per share on revenue of $34.59 billion. 
Via Benzinga
Short Volatility Alert: IVERIC bio, Inc.
On Wednesday, shares of IVERIC bio, Inc. (NASDAQ: ISEE) experienced volatile short activity. After the activity, the stock price went up +1.70% to $11.95. The overall sentiment for ISEE has been... 
Via Benzinga
Expert Ratings for IVERIC bio
IVERIC bio (NASDAQ:ISEE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Several Chinese Stocks Traded Higher; Here Are 58 Biggest Movers From Yesterday
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) surged 95.3% to close at $0.2580 on Thursday after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and announced a price target... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From IVERIC bio, Inc.
Via Business Wire
7 Cheap Biotech Stocks to Buy Now
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022
From IVERIC bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Upgrades 
Via Benzinga
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
3 Biotech Stock Picks From This Wedbush Analyst
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June. 
Via Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Alibaba, General Electric And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Redbox Entertainment Inc. (NASDAQ: RDBX) rose 11.5% to $6.19 in pre-market trading after jumping 82% on Monday. 
Via Benzinga
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank
From IVERIC bio, Inc.
Via Business Wire
Earnings Preview: IVERIC bio
IVERIC bio (NASDAQ:ISEE) is set to give its latest quarterly earnings report on Tuesday, 2022-07-26. Here's what investors need to know before the announcement. Analysts estimate that IVERIC bio will... 
Via Benzinga
Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting
From IVERIC bio, Inc.
Via Business Wire
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®
From IVERIC bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.